Notably, TAK-981 treatment also led to the significant downregulation of several genes associated with resistance to doxorubicin, which is used in the treatment of synovial sarcoma(Barreto Coelho et al, 2021) (Fig. 4C,D) as assessed using gene set enrichment analysis (GSEA) (Subramanian et al, 2005). This evidence concerns the gene CDK9 and synovial sarcoma.